ArticleClinical and translational radiation oncology2026
High-dose-rate monotherapy for localised prostate Cancer: A two-implant approach with median 13 years follow-up.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To report the clinical outcome of High-Dose-Rate (HDR) brachytherapy (BRT) as sole treatment for clinically localised prostate cancer (PCA). Methods: From March 2004 to January 2008, 351 consecutive patients with clinically localised PCA were treated with HDR monotherapy receiving two BRT implants, separated by 14 days, each delivering two fractions at 9.5 Gy to an intraoperative transrectal ultrasound real-time defined planning treatment volume Results: The median follow-up for the current analysis was 158 months with 201 patients eligible for analysis. Out of the initial cohort, 62 patients died during follow-up and 150 were lost to follow-up. The 60-, 120- and 158-months biochemical control and metastasis-free survival rates were 94%, 90%, 86% and 97%, 89%, 83%, respectively. Eight (3.9%) patients developed late Grade 2-3 lower urinary tract symptoms characterized by increased urgency and frequency with no dysuria or incontinence > Grade 2. Four (2%) patients developed late Grade 3 gastrointestinal toxicity. No Grade 4 or higher acute or late toxicities occurred. Conclusions: Our results confirm HDR-BRT to be a safe and effective monotherapy for organ-confined PCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.